Imipramine: Therapeutic Indications
Imipramine is primarily used for treating depression in adults and as third-line therapy for childhood nocturnal enuresis (bedwetting) in children 6 years and older. 1
Primary Indications
Depression
Imipramine is FDA-approved for treating depression in adults, with dosing ranging from 75-300 mg/day depending on whether the patient is hospitalized or outpatient 1. The drug demonstrates 40-60% effectiveness in treating major depressive disorder, though relapse rates can reach 50% 2. For chronic depression, including dysthymic disorder, imipramine shows marked favorable responses in 45% of patients versus 12% with placebo 3.
Childhood Enuresis (Bedwetting)
Imipramine is approved only as third-line therapy for nocturnal enuresis in children 6 years and older, after behavioral interventions (enuresis alarms) and desmopressin have failed 4. The drug achieves approximately 50% response rates in therapy-resistant enuresis 4. Dosing starts at 25 mg at bedtime for children 6 and older, increasing to 50 mg for children under 12 years, or up to 75 mg for those over 12 years 1. A maximum dose of 2.5 mg/kg/day should never be exceeded in children 1.
Off-Label Uses (Based on Evidence)
Neuropathic Pain
Imipramine serves as a coanalgesic for cancer-related neuropathic pain, typically at doses of 10-25 mg nightly, increased to 50-150 mg as tolerated 5. The analgesic effect occurs at lower doses and more rapidly than its antidepressant action 2.
Generalized Anxiety Disorder
Evidence shows imipramine reduces anxiety in GAD patients, though its metabolite desipramine may counteract therapeutic effects 6. Higher desipramine levels correlate with poorer treatment response 7.
Critical Safety Considerations
Cardiotoxicity Risk
The central problem with imipramine is its potential cardiotoxicity—overdose may prove fatal 4. Before initiating treatment:
- Obtain baseline ECG to exclude underlying rhythm disorders, especially if there is any history of palpitations, syncope, sudden cardiac death in the family, or unstable arrhythmia 4, 2
- Screen for long QT syndrome with prolonged ECG recording if family history is concerning 4
- Keep medication securely locked away from younger siblings 4, 2
Suicidality Warning
All patients, particularly children and adolescents, must be monitored closely for clinical worsening, suicidality, and unusual behavioral changes, especially during the initial months of therapy or dose changes 1. Prescriptions should be written for the smallest quantity consistent with good management 1.
Common Side Effects
- Mood changes, nausea, insomnia (often appearing before beneficial effects) 4
- Anticholinergic effects: dry mouth, urinary hesitancy, constipation 5
- Tolerance develops with chronic use, requiring drug holidays of at least 2 weeks every 3 months 4
Positioning in Treatment Algorithms
For depression: Imipramine is no longer first-line due to safety concerns. Preferred agents include SSRIs (citalopram, escitalopram, sertraline), SNRIs (venlafaxine), or other newer antidepressants with more favorable safety profiles 8.
For enuresis: Use only after:
- Behavioral interventions (enuresis alarm) have failed
- Desmopressin has failed or is unaffordable
- At tertiary care facilities with appropriate monitoring 4
For neuropathic pain: Consider as coanalgesic alongside opioids when pain is partially responsive, though secondary-amine tricyclics (nortriptyline, desipramine) are better tolerated than imipramine 5, 8.
Therapeutic Drug Monitoring
Monitor plasma levels when there is no response despite adequate dosing (2.5 mg/kg/day in children, 200+ mg/day in adults) 2. Importantly, high desipramine metabolite levels correlate with treatment failure—consider individual metabolite levels, not just combined imipramine plus desipramine levels 7.